Neither moxifloxacin nor cefuroxime produces significant attenuation of inflammatory mediator release in patients exposed to cardiopulmonary bypass: A randomized controlled trial

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 230-233

  Wiesner, Gunther ^a   Braun, Siegmund Lorenz ^a   Gruber, Michael ^b   Gertler, Ralph ^a   Lange, Rüdiger ^a   Tassani, Peter ^a   Martin, Klaus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cardiac surgery; Cephalosporins; Fluoroquinolones; Inflammation

Indexed keywords

CEFUROXIME; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MOXIFLOXACIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; HETEROCYCLIC COMPOUND; IMMUNOLOGIC FACTOR; QUINOLINE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CYTOKINE RESPONSE; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; SECRETION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTIBIOTIC PROPHYLAXIS; AZA COMPOUNDS; CARDIOPULMONARY BYPASS; CEFUROXIME; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859173930     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr397     Document Type: Article

References (10)

1. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003; 3: 359-71.
2. Kellermann K, Dertinger N, Blobner M et al. Perioperative moxifloxacin treatment in rats subjected to deep hypothermic circulatory arrest: Reduction in cerebral inflammation but without improvement in cognitive performance. J Thorac Cardiovasc Surg 2011; 141: 796-802.
3. Warren OJ, Smith AJ, Alexiou C et al. The inflammatory response to cardiopulmonary bypass: part 1 - mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23: 223-31.
4. Tassani P, Richter JA, Eising GP et al. Influence of combined zero-balanced and modified ultrafiltration on the systemic inflammatory response during coronary artery bypass grafting. J Cardiothorac Vasc Anesth 1999; 13: 285-91.
5. Welters ID, Feurer MK, Preiss V et al. Continuous S-(+)-ketamine administration during elective coronary artery bypass graft surgery attenuates pro-inflammatory cytokine response during and after cardiopulmonary bypass. Br J Anaesth 2011; 106: 172-9.
6. Zimmermann GS, Neurohr C, Villena-Hermoza H et al. Anti-inflammatory effects of antibacterials on human bronchial epithelial cells. Respir Res 2009; 10: 89.
7. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 Suppl B: 83-90.
8. Harms H, Prass K, Meisel C et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One 2008; 3: e2158.
9. Klehmet J, Harms H, Richter M et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009; 158: 1184-93.
10. Trautmann M, Scheibe C, Wellinghausen N et al. Low endotoxin release from Escherichia coli and Bacteroides fragilis during exposure to moxifloxacin. Chemotherapy 2010; 56: 364-70.